ReviewWorld journal of surgical oncology2026
Research progress on early diagnostic markers for pancreatic cancer.
Review in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Pancreatic cancer (PC) is a highly aggressive malignancy characterized by insidious onset, rapid progression, and poor prognosis, predominantly affecting middle-aged and elderly men. Biomarker detection represents the most widely utilized approach for early PC diagnosis, encompassing both traditional and novel categories. Although traditional biomarkers like CA 19 - 9 are widely employed clinically, they carry a risk of false negatives in Lewis antigen-negative individuals, underscoring the urgent need for multi-parameter detection strategies to enhance accuracy. Integrating core indicators such as CEA and CA 242 can significantly improve the diagnostic effect of early PC and optimize diagnosis and treatment decisions. In recent years, breakthroughs have been made in biomarkers. Novel detection methods such as liquid biopsy and exosomes are entering the scope of clinical application. Due to their non-invasive nature, good sensitivity and specificity, these innovative biomarkers are gradually replacing traditional biomarkers and have become a new research focus. At present, single traditional biomarkers have limitations in diagnosing PC, while novel biomarkers lack extensive clinical verification. Meanwhile, there is no systematic review article specifically for early screening of PC to comprehensively evaluate the value and application prospects of these biomarkers. Therefore, this article provides a narrative review and comprehensive overview of the research progress on biomarkers related to the early diagnosis of PC in recent years.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.